- Amarin Corporation plc (NASDAQ:AMRN) continues suspending 2022 revenue guidance citing the ongoing global impact of COVID-19, the uncertainty resulting from the impact of generic IPE availability in the U.S., and challenges for most drugs seeking market access in Europe.
- “In the second quarter of 2022, we made important progress on our long-term growth strategy. Our achievements give us confidence in the direction of and opportunities for Amarin during the remainder of 2022 and into 2023,” said CEO Karim Mikhail.
- Amarin reiterates that current cash, investments, and other assets are adequate to support continued operations, including European launch activities for at least the next twelve months.
- The company reported Q2 sales of $94.4 million, a decrease of 39% driven by a decline in volume and net selling price due to an increase in generic competition in the U.S.
- During Q2, there were three generic competitors in the U.S. market compared to one a year ago.
- Amarin’s gross margin on net product revenue was 46%, compared with 79% a year ago. The adjusted gross margin was 72%.
- Amarin posted an adjusted EPS loss of $(0.09), a shift from a profit of $0.03 a year ago and missing the consensus loss of $(0.06).
- Price Action: AMRN shares are down 1.57% at $1.30 during the market session on the last check Wednesday.
Alexandria Real Estate Equities Declares Cash Dividend of $1.21 Per Common Share For Q4 2022 From $1.18 Per Share In Q3 2022, And An Aggregate Of $4.72 Per Common Share For 2022, Up $0.24, Or 5% Over 2021
Alexandria Real Estate Equities, Inc. (NYSE:ARE) today announced that its Board of Directors declared a quarterly cash dividend of $1.21 per common share for the fourth quarter of 2022. The
